Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Biotechnology

Healthcare
$0.31 -0.58%

-$0.00 today

Market cap
$69.95M
Beta
2.82
P/E (TTM)
-1.3
EPS (TTM)
-$0.54
52W Low $0.53High $2.35

Volume 2.77M

Average 3.79M

TNYA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Tenaya Therapeutics, Inc.NASDAQ: TNYA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at -683.6%

Gross margin was -683.6% in Q1 FY2026. On a trailing-twelve-month basis it was 144.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-683.6%— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
144.9%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

No Gross Margin data reported for this period type.

Gross Margin vs competitors

How TNYA compares with its peers on the latest reported figures

  • TNYA's LTM Mar 2026 gross margin of 144.9% is the highest of the 9 companies compared; the peer median is 67.3%.
TNYA Competitors Peer median
Gross Margin for TNYA and competitors
Company Period LTM level YoY 3-year change
TNYATenaya Therapeutics, Inc.LTM Mar 2026144.9% ——
PYXSPyxis Oncology, Inc.LTM Mar 202699.8% ——
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 202698.3% -1.7 pp-7.0 pp
PRLDPrelude Therapeutics IncorporatedLTM Mar 202697.7% -2.3 pp—
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
ABEOAbeona Therapeutics Inc.LTM Mar 202651.9% —+5.5 pp
FHTXFoghorn Therapeutics Inc.LTM Mar 202622.3% -77.7 pp-10.8 pp
VYGRVoyager Therapeutics, Inc.LTM Mar 2026-86.7% +2.3 pp+136.3 pp
HUMAHumacyte, Inc.LTM Mar 2026-748.5% -729.4 pp-309.0 pp
NAUTNautilus Biotechnology, Inc.FY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding TNYA) 67.3%-2.0 pp-6.7 pp

Competitors are the stored peer set for TNYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue4.03M8.71M8.69M8.47M8.44M
Gross Profit(4.03M)(8.71M)(8.69M)(8.47M)(8.44M)
Gross Margin—————
Research & Development54.39M94.54M98.04M86.74M68.61M
Selling, General & Admin14.39M22.37M24.47M20.74M24.72M
Operating Expenses68.78M116.91M122.51M107.48M84.9M
Depreciation & Amortization4.03M8.71M8.69M8.47M8.44M
EBITDA(68.7M)(114.95M)(115.4M)(102.66M)(82.16M)
EBITDA Margin—————
Operating Income(72.81M)(125.62M)(131.19M)(115.95M)(93.33M)
Operating Margin—————
Interest Income108K1.95M7.06M4.74M2.68M
Interest Expense00000
Other Income / Expenses85K1.96M7.11M4.82M2.73M
Income Before Tax(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(72.72M)(123.67M)(124.08M)(111.13M)(90.6M)
Net Margin—————
EPS (Basic)(1.69)(2.76)(1.68)(1.31)(0.59)
EPS (Diluted)(1.69)(2.76)(1.68)(1.31)(0.59)
Weighted Avg Shares41.29M44.82M73.79M84.82M152.97M
Weighted Avg Shares (Diluted)41.29M44.82M73.79M84.82M152.97M

Tenaya Therapeutics, Inc.

NASDAQ:TNYA

Intrinsic Alpha fair value

Locked

Current Price

$0.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.